is associated with neurologic disorders that may include, but are not
limited to, multiple sclerosis (MS), amyotrophic lateral sclerosis
(ALS), dementias including Alzheimer's disease, Parkinson's disease,
stroke and traumatic brain injury.”
Both Zenvia 30/10 mg and
20/10 mg exhibited a statistically significant reduction in episode
rates over the course of the study when compared to placebo.
company currently expects to curtail additional sales under the
facility in the near future and will assess its funding needs to
determine the necessity for other financing alternatives.